Diamonds and Dogs
6/16/14
Bluebird Bio, Inc. (BLUE)Bluebird Bio starts the week off with strong results from its gene therapy treatment, called LentiGlobin. The process was successful in replacing non-functional genes with functional ones. Two patients that were suffering from an inherent blood disease were able to stop relying on blood transfusions and were producing functional hemoglobin after a single session with LentiGlobin. Bluebird Bio was up 53% pre-market, but was at about a 35% gain at $35 around 1 p.m. The stock rocketed to a new 52-week high of $41.77 and was at a volume of almost 4.5 million by one o'clock. This is a strong start to the week for a biotechnology company that could have a bright future.
DreamWorks Animation (DWA)
Following the release of the sequel How to Train Your Dragon 2, DreamWorks Animation saw a drop in its stock price Monday morning. By early afternoon, DWA was down 12% to about $24. This resulted from a weak first weekend for the new dragon-filled movie, and a failure to compensate for low revenues from past productions, such as Mr. Peabody and Sherman. Bullish investors were disappointed when the movie resulted in only $50 million in box-office revenue compared to an optimistic $60 million estimate. With revenues continuing to drop lower and lower, DreamWorks' outlook over the next few quarters is bearish.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.